Norprolac®

Non-ergot-derived¹ – for added peace of mind in hyperprolactinaemia

- An in-vitro study showed that the difference in potency between effects at D₂₅ and 5-HT₁₆ receptors is greatest for quinaagolide (2100x), followed by cabergoline (290x) and bromocriptine (50x)⁴
- On this basis quinaagolide may have the greatest safety margin between dopaminergic and serotonergic side effects⁴
- Licensed for use up to the point of pregnancy is confirmed⁴
- Improved tolerability compared to bromocriptine⁴

Prescribing Information: Norprolac® Tablets: Please consult the full Summary of Product Characteristics before prescribing. Name of Product: Norprolac® Tablets 25, 50 and 75 micrograms. Indications: Non-ergot-derived dopamine agonist used in the management of hyperprolactinaemia. Recommended dosage: 25 micrograms for the first 3 days, followed by 50 micrograms daily for a further three days. From day 7, the recommended dose is 75 micrograms. Usual maintenance dose is 75 to 150 micrograms. These recommendations are based on efficacy and safety. Contraindications: Use in pregnancy or breast-feeding. Hypersensitivity to quinaagolide. Reducing prolactin. Restoring menstrual cycles

Norprolac® quinaagolide

Reducing prolactin. Restoring menstrual cycles

Adverse events should be reported. Reporting forms and information can be found at www.medicines.org.uk

NORFERRING
Ferring Pharmaceuticals Ltd, The Courtyard, Westmore Drive, London, SE8 5NL, UK. Tel: 020 7809 8400. Internet: ferring.com

Date of Preparation: March 2009